Mubasher: France’s Biocorp inked a partnership agreement with pharmaceutical giant Sanofi for the use of the medical device maker’s connected device for insulin pens, Mallya, according to the Issoire-based company's press release.

Sanofi will make a second payment of EUR 2 million ($2.22 million) to Biocorp, once the deal is signed, after paying an initial tranche of EUR 4 million last July, when the two companies started their negotiations.

Sanofi will also pay EUR 1.5 million in 2020, after when the device is launched on the market.

“Mallya has the potential to be a blockbuster thanks to the competitive advantages it brings to patients in monitoring the follow-up of their diabetes,” Biocorp’s COO Éric Dessertenne said.

Under the agreement, Sanofi will acquire the right to non-exclusively distribute the current version of the Mallya worldwide as from next year.

Biocorp will develop, at its production plan in Issoire, a version of Mallya specifically designed for Sanofi’s insulin pen, SoloStar.

“Thanks to SANOFI's global reach, this device will help improve compliance for the largest number of patients with diabetes,” Dessertenne noted.